EAM
PRCT icon

Exome Asset Management’s Procept Biorobotics PRCT Stock Holding History

Exome Asset Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,900
Closed -$1.42M – 82
2025
Q3 		$1.42M Buy
+39,900
New +$1.82M 0.86% 43

Other funds holding PRCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Exome Asset Management's PRCT Position: Q4 2025 in Review

Exome Asset Management sold out of Procept Biorobotics (PRCT) in Q4 2025, closing a stake of 39,900 shares — an estimated $1.42M sold.

Exome Asset Management first reported a position in PRCT in Q3 2025 and held it in 1 quarter. The position peaked at $1.42M in Q3 2025. 263 funds tracked by Wall St. Rank hold PRCT as of Q4 2025.

  • Exome Asset Management reported no remaining Procept Biorobotics position as of Q4 2025 after selling out during the quarter.
  • Exome Asset Management sold 39,900 Procept Biorobotics shares in Q4 2025, an estimated $1.42M.
  • Exome Asset Management first reported a position in Procept Biorobotics in Q3 2025 and held it in 1 quarter.
  • Exome Asset Management's Procept Biorobotics position peaked at $1.42M in Q3 2025.
  • 263 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.